SGLT-2抑制剂与GLP-1受体激动剂对糖尿病合并慢性肾脏病患者的肾脏与心脏保护作用:EURECA-m与DIABESITY工作组共识
该共识由ERA-EDTA的EURECA-m和DIABESITY工作组制定,汇总证据表明SGLT-2抑制剂和GLP-1受体激动剂可降低2型糖尿病患者的CVD事件、全因死亡及肾脏病进展,并讨论其机制与在CKD合并DM患者中的治疗地位。
要点
- SGLT-2抑制剂和GLP-1受体激动剂在T2DM患者中具有心血管和肾脏保护作用。
- 上述药物可减少CV事件、全因死亡及肾脏病进展。
- 共识讨论了两类药物在CKD合并DM患者中的治疗定位。
核心结论
- SGLT-2抑制剂和GLP-1受体激动剂在T2DM患者中可降低CV事件、全因死亡和肾脏病进展。
研究设计与样本
- 本文件为ERA-EDTA的EURECA-m和DIABESITY工作组发布的共识声明。
主要发现
- 近期随机安慰剂对照结局试验显示SGLT-2抑制剂和GLP-1受体激动剂可减少CV事件和全因死亡。
- 上述试验还显示两类药物可减少T2DM患者的肾脏病进展。
- 两类药物除降糖外还有减重和降压等有益效应。
临床怎么用
- 共识详细呈现了两类药物心肾保护作用的现有证据并分析潜在机制。
- 共识讨论了SGLT-2抑制剂和GLP-1受体激动剂在CKD合并DM患者治疗中的地位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM have emerged, including inhibitors of renal sodium-glucose co-transporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, these classes were reported to have other beneficial effects for the cardiovascular and renal systems, such as weight loss and blood pressure reduction. Most importantly, in contrast to all previous studies with anti-diabetic agents, a series of recent randomized, placebo-controlled outcome trials showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events and all-cause mortality, as well as progression of renal disease, in patients with type 2 DM. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of SGLT-2 inhibitors and GLP-1 analogues, analyses the potential mechanisms involved in these actions and discusses their place in the treatment of patients with CKD and DM.
引用
- Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019. PMID: 30753708. doi:10.1093/ndt/gfy407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。